The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update

Affiliations

• ¹ Pharmaceutical Sciences Department, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
• ² 1] Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado, Denver, Colorado, USA [2] Clinical Pharmacy Services, Kaiser Permanente Colorado, Denver, Colorado, USA.
• ³ Department of Medicine, Duke University, Durham, North Carolina, USA.
• ⁴ 1] IMAGENETICS, Sanford Medical Center, Fargo, North Dakota, USA [2] Department of Medicine, University of North Dakota, Fargo, North Dakota, USA.
• ⁵ Department of Clinical Pharmacy and Outcomes Sciences, South Carolina College of Pharmacy, Columbia, South Carolina, USA.
• ⁶ Personalized Medicine Institute, Moffitt Cancer Center, Tampa, Florida, USA.
• ⁷ Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, California, USA.
• ⁸ 1] Oates Institute for Experimental Therapeutics, Vanderbilt University Medical Center, Nashville, Tennessee, USA [2] Department of Medicine, Division of Clinical Pharmacology, Vanderbilt University, Nashville, Tennessee, USA.
• ⁹ Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics and Division of Cardiovascular Medicine, University of Florida, Gainesville, Florida, USA.
• ¹⁰ Department of Genetics, Stanford University, Palo Alto, California, USA.
• ¹¹ Department of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
• ¹² 1] Department of Clinical Pharmacology, University of Helsinki and HUSLAB, Helsinki University Central Hospital, Helsinki, Finland [2] King Abdulaziz University , Jeddah, Saudi Arabia.